Skip to main content
. Author manuscript; available in PMC: 2023 Jun 18.
Published in final edited form as: Metabolism. 2021 Oct 27;126:154920. doi: 10.1016/j.metabol.2021.154920

Fig. 3.

Fig. 3.

The epigenetic tools, writers/readers/erasers, and noncoding RNAs (miRNA, LncRNA etc.) are altered in diabetes, contributing in the development of diabetic complications. Recent technical advances have identified many small molecule componds that can interfere in the activation/inhibition of these epigenetic tools and target noncoding RNAs. Some of them are in pre-clinical or clinical trials for other chronic diseases (e.g., cancer), and the future for such epigenetic drugs for treating diabetic complications looks promising. (MBD = Methyl-CpG binding domain).